Life Tech Reports iGenomics to Buy 32 Ion Proton Next-Gen Sequencers
Life Technologies Corporation (NASDAQ: LIFE) today announced that iGenomics, a privately held diagnostic service company based in Guangzhou, China, purchased 17 Ion Proton™ sequencers and plans to add 15 more instruments by the end of the year. iGenomics, which also signed a licensing and supply agreement with Life Technologies, will initially use the sequencers for research in aneuploidy screening, but plans to expand into other research applications.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.